Oruka Therapeutics ORKA
Oruka Therapeutics reported a $49.97 million net loss for Q3 2026.
Oruka Therapeutics (ORKA) filed a 10-Q with the SEC on Nov 9, 2026, 4:03 pm ET. Source: the filing on SEC EDGAR.
Quarterly report for the period ended Sep 30, 2026, 27 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001213900-26-117518
- Net loss: $49.97 million for the three months ended Sep 30, 2026
- Cash and equivalents: $191.52 million at Sep 30, 2026
- Research and development expenses: $53.696 million for the three months ended Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
27 new risk factors · 41 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change QoQ | |
|---|---|---|---|
| Cash | $191.52M | $268.47M | −29% |
New risk factors (27)
- The summary below is not exhaustive and is qualified by reference to the full set of risk factors set forth in Item 1A "Risk Factors" of this Quarterly Report. Please carefully consider all the information in this Quarterly Report, including the full set of risks set forth in the "Risk Factors" section, and in our…
- ● We have never generated revenue from product sales and may never be profitable.
- Risks Related to Clinical Development, Regulatory Approval and Commercialization
- Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Risks Related to Owning Our Common Stock
- ● Our business could be adversely affected by macroeconomic or geopolitical conditions.
- and 22 more in the filing
Removed risk factors (41)
- exhaustive and is qualified by reference to the full set of risk factors set forth in Item 1A "Risk Factors" of this Quarterly +2 more paragraphs
- be available in sufficient amounts or on reasonable terms, if at all. The current market environment for small and midcap biotechnology companies and broader macroeconomic factors may preclude us from successfully raising additional capital on the timeline we require. +3 more paragraphs
- additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Debt financing and… +3 more paragraphs
- of ORKA-002 in healthy volunteers is fully enrolled and remains ongoing for purposes of continued patient follow-up and data collection, and remains blinded. In addition, we commenced a Phase 2 clinical trial of ORKA-002 in patients with moderate-to-severe PsO in February +1 more paragraph
- the timing of the anticipated accomplishment of various scientific, clinical, regulatory, or other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing of our clinical… +2 more paragraphs
- and 36 more in the filing